Cargando…
The Effect of Upadacitinib on Lipid Profile and Cardiovascular Events: A Meta-Analysis of Randomized Controlled Trials
Background: Our aim was to systematically investigate the effect of upadacitinib, an oral JAK-1 selective inhibitor, on lipid profile and cardiovascular disease risk. Methods: PubMed, PubMed Central and ClinicalTrials.gov databases were searched for relevant randomized controlled trials (RCTs) up to...
Autores principales: | Makris, Anastasios, Barkas, Fotios, Sfikakis, Petros P., Liberopoulos, Evangelos, Agouridis, Aris P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740350/ https://www.ncbi.nlm.nih.gov/pubmed/36498468 http://dx.doi.org/10.3390/jcm11236894 |
Ejemplares similares
-
Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?
por: Makris, Anastasios, et al.
Publicado: (2023) -
Bradycardia and coronavirus disease 2019: What is behind?
por: Barkas, Fotios, et al.
Publicado: (2021) -
Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis
por: Barkas, Fotios, et al.
Publicado: (2020) -
Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials
por: Barkas, Fotios, et al.
Publicado: (2021) -
Statin-associated side effects in patients attending a lipid clinic: evidence from a 6-year study
por: Barkas, Fotios, et al.
Publicado: (2021)